Rana Aldisi

Rana Aldisi

Auto-generated profile, based on publicly available information

Rana Aldisi

Institute for Genomic Statistics and Bioinformatics, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
CHCharles Tapley Hoyt
Charles Tapley Hoyt
DDDaniel Domingo
Daniel Domingo
RARana Aldisi
Rana Aldisi
LXLingling Xu
Lingling Xu
KKKristian Kolpeja
Kristian Kolpeja
MHMartin Hofmann-Apitius
Martin Hofmann-Apitius
The rapid accumulation of new biomedical literature not only causes curated knowledge graphs (KGs) to become outdated and incomplete, but also makes manual curation an impractical and unsustainable solution. Automated or semi-automated workflows are necessary to assist in prioritizing and curating the literature to update and enrich KGs. We have developed two workflows: one for re-curating a given KG to assure its syntactic and semantic quality and another for rationally enriching it by manually revising automatically extracted relations for nodes with low information density. We applied these workflows to the KGs encoded in Biological Expression Language from the NeuroMMSig database using content that was pre-extracted from MEDLINE abstracts and PubMed Central full-text articles using text mining output integrated by INDRA. We have made this workflow freely available at https://github.com/bel-enrichment/bel-enrichment.

17 August 2016 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
OZOsama K Zaki
Osama K Zaki
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
HAHeba S El Abd
Heba S El Abd
SHSoumaya A Harche
Soumaya A Harche
RMReem A Mattar
Reem A Mattar
HZHatem Zayed
Hatem Zayed

1 July 2018 in Sexually Transmitted Diseases
Verified
Journal Article
Open access
SDSoha R. Dargham
Soha R. Dargham
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
EAEnas Said AL Absi
Enas Said AL Absi
LMLayla I. Bsc Mohammed
Layla I. Bsc Mohammed
RARana S. Bsc Al-Disi
Rana S. Bsc Al-Disi
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
Background: There are limited data on herpes simplex virus type 2 (HSV-2) seroprevalence in the Middle East and North Africa (MENA). We examined country- and age-specific HSV-2 seroprevalence among select MENA populations residing in Qatar. Methods: Sera were collected from male blood donors attending Hamad Medical Corporation between June 2013 and June 2016. Specimens were screened for anti-HSV-2 IgG antibodies following a 2-test algorithm: HerpeSelect 2 ELISA was used to identify HSV-2–positive specimens, and Euroline-WB was used to confirm positive and equivocal specimens for final HSV-2 status. Trends and associations with HSV-2 seropositivity were assessed. Results: Of the 2077 tested sera, 61 were found and confirmed positive. The proportion of those confirmed positive increased steadily with HerpeSelect 2 ELISA index value, ranging from 16.3% for index values of 1.101 to 1.999 to 92.9% for index values of 4 or greater. Nationality-specific seroprevalence was 6.0% (95% confidence interval [CI], 4.1%–8.8%) in Qataris, 5.3% (95% CI, 2.5%–11.1%) in Iranians, 4.2% (95% CI, 1.8%–9.5%) in Lebanese, 3.1% (95% CI, 1.2%–7.7%) in Sudanese, 3.0% (95% CI, 1.4%–6.4%) in Palestinians, 2.2% (95% CI, 1.1%–4.3%) in Egyptians, 2.0% (95% CI, 1.0%–5.0%) in Syrians, 1.0% (95% CI, 0.3%–3.6%) in Jordanians, 0.7% (95% CI, 0.1%–3.7%) in Yemenis, and 0.5% (95% CI, 0.1%–2.8%) in Pakistanis. There was evidence for higher seroprevalence in older age groups. Conclusions: The seroprevalence of HSV-2 was in the range of few percentage points. There were no major differences in seroprevalence by nationality. These findings add to our understanding of HSV-2 epidemiology in MENA and indicate unmet needs for sexual health and control of sexually transmitted infections.

1 June 2018 in Journal of Clinical Virology
Verified
Journal Article
Open access
RARana S. Aldisi
Rana S. Aldisi
MEMalaz S. Elsidiq
Malaz S. Elsidiq
SDSoha R. Dargham
Soha R. Dargham
ASAfifah S. Sahara
Afifah S. Sahara
EAEnas S. Al-Absi
Enas S. Al-Absi
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
The number of diagnostic assays for the detection of herpes simplex virus type 1 (HSV-1) antibodies has increased over the years. However, their performance characteristics could vary among global populations. To investigate performance of two commercial ELISA kits, HerpeSelect® 1 ELISA and Euroimmun Anti-HSV-1 (gC1) ELISA (IgG); and two commercial immunoblot (IB)/Western blot (WB) assays, HerpeSelect® 1 and 2 Immunoblot IgG, and Euroimmun Anti-HSV-1/HSV-2 gG2 Euroline-WB (IgG/IgM); in detecting HSV-1 antibodies in a Middle East and North Africa (MENA) population. Blood specimens were collected from blood donors in Doha, Qatar, June 2013-2016. Twenty specimens were randomly selected from 10 MENA nationalities (Egypt, Iran, Jordan, Lebanon, Pakistan, Palestine, Qatar, Sudan, Syria, and Yemen; total = 200), and tested for HSV-1 antibodies. Across all six comparisons between assays, positive percent agreement ranged between 95.7% (95% CI: 91.4-98.3%) and 100.0% (95% CI: 97.8-100.0%). Negative percent agreement ranged between 86.2% (95% CI: 68.3-96.1%) and 96.2% (95% CI: 80.4-99.9%). Overall percent agreement ranged between 95.7% (95% CI: 91.7-97.8%) and 99.4% (95% CI: 96.7-99.9%). Cohen's kappa statistic ranged between 0.84 (95% CI: 0.73-0.95) and 0.98 (95% CI: 0.93-1.00). Compared against IB/WB, HerpeSelect® and Euroimmun had sensitivities and specificities >96% and >86%, respectively. Positive and negative predictive values were >97% and >83%, respectively. The assays showed excellent concordance with one another, and with a high kappa statistic. The ELISA kits demonstrated robust diagnostic performance compared to the IB/WB assays. These findings support the assays' utility in clinical diagnosis and research in MENA populations.

22 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHSabrina Katrin Henne
Sabrina Katrin Henne
RARana Aldisi
Rana Aldisi
SSSugirthan Sivalingam
Sugirthan Sivalingam
LHLara Maleen Hochfeld
Lara Maleen Hochfeld
OBOleg Borisov
Oleg Borisov
SHStefanie Heilmann-Heimbach
Stefanie Heilmann-Heimbach
Male-pattern hair loss (MPHL) is common and highly heritable. While genome-wide association studies (GWAS) have generated insights into the contribution of common variants to MPHL etiology, the relevance of rare variants remains unclear. To determine the contribution of rare variants to MPHL etiology, we perform gene-based and single-variant analyses in exome-sequencing data from 72,469 male UK Biobank participants. While our population-level risk prediction suggests that rare variants make only a minor contribution to general MPHL risk, our rare variant collapsing tests identified a total of five significant gene associations. These findings provide additional evidence for previously implicated genes (EDA2R, WNT10A) and highlight novel risk genes at and beyond GWAS loci (HEPH, CEPT1, EIF3F). Furthermore, MPHL-associated genes are enriched for genes considered causal for monogenic trichoses. Together, our findings broaden the MPHL-associated allelic spectrum and provide insights into MPHL pathobiology and a shared basis with monogenic hair loss disorders.

10 March 2022 in Bioinformatics
Verified
Journal Article
Open access
PDF file
RARana Aldisi
Rana Aldisi
EHEmadeldin Hassanin
Emadeldin Hassanin
SSSugirthan Sivalingam
Sugirthan Sivalingam
ABAndreas Buness
Andreas Buness
HKHannah Klinkhammer
Hannah Klinkhammer
CMCarlo Maj
Carlo Maj
The genetic architecture of complex traits can be influenced by both many common regulatory variants with small effect sizes and rare deleterious variants in coding regions with larger effect sizes. However, the two kinds of genetic contributions are typically analyzed independently. Here, we present GenRisk, a python package for the computation and the integration of gene scores based on the burden of rare deleterious variants and common-variants-based polygenic risk scores. The derived scores can be analyzed within GenRisk to perform association tests or to derive phenotype prediction models by testing multiple classification and regression approaches. GenRisk is compatible with VCF input file formats. GenRisk is an open source publicly available python package that can be downloaded or installed from Github (https://github.com/AldisiRana/GenRisk). Supplementary data are available at Bioinformatics online.